 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| TBio-6517 / Turnstone Biologics
Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=27, Terminated, Sponsor: Turnstone Biologics, Corp.
Trial completion date: Dec 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2023; Sponsor decision
- ||| TBio-6517 / Turnstone Biologics
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=27, Active, not recruiting, Sponsor: Turnstone Biologics, Corp.
Trial completion date: Dec 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2023; Sponsor decision Recruiting --> Active, not recruiting | N=138 --> 27 | Trial completion date: Jul 2025 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Jun 2023
- || TBio-6517 / Turnstone Biologics
Trial completion date, Trial primary completion date, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Feb 22, 2022
P1/2, N=138, Recruiting, Sponsor: Turnstone Biologics, Corp.
Recruiting --> Active, not recruiting | N=138 --> 27 | Trial completion date: Jul 2025 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Jun 2023 Trial completion date: Dec 2022 --> Jul 2025 | Trial primary completion date: Aug 2022 --> Dec 2024
- ||||| TBio-6517 / Turnstone Biologics, Takeda
Clinical, Oncolytic virus: .@TurnstoneBio to advance #immunooncology portfolio after oversubscribed $80M #SeriesD #financing round Focused on #TIL #immunotherapy & #OncolyticViruses, incl RIVAL-01 in Ph1/2a #ClinicalTrials in solid #tumors https://t.co/UfYqnqCOd5 #cancers @TakedaOncology (Twitter) - Jul 21, 2021
- ||| TBio-6517 / Turnstone Biologics
Enrollment change, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - May 6, 2021
P1/2, N=114, Recruiting, Sponsor: Turnstone Biologics, Corp.
Trial completion date: Dec 2022 --> Jul 2025 | Trial primary completion date: Aug 2022 --> Dec 2024 N=84 --> 114
- ||| TBio-6517 / Turnstone Biologics
Enrollment open, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Jun 8, 2020
P1/2, N=84, Recruiting, Sponsor: Turnstone Biologics, Corp.
N=84 --> 114 Not yet recruiting --> Recruiting
- |||| TBio-6517 / Turnstone Biologics
New P1/2 trial, Combination therapy, Oncolytic virus, Metastases: RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Mar 9, 2020
P1/2, N=84, Not yet recruiting, Sponsor: Turnstone Biologics, Corp.
- TBio-6517 / Turnstone
Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1166;
Our new best-in-class recombinant VACV robustly stimulates systemic anti-tumor immunity and has a substantially improved pre-clinical safety profile compared to other VACV clinical candidates. Additional ongoing toxicity and efficacy studies are being conducted prior to clinical evaluation of the novel virus construct.